Sweden's Elicera Q4 operating loss widens

Elicera Therapeutics AB

13/02/2026 07:28

Overview

Swedish biotech firm's Q4 operating loss widened to SEK -7.1 mln from SEK -2.9 mln

Q4 loss per share was SEK -0.14, compared to SEK -0.07 last year

Company continues CARMA study with promising results in lymphoma patients

Outlook

Elicera plans to present CARMA study data update in Q2 2026

Company actively seeks financing for preclinical programs, focusing on ELC-401

Elicera evaluating strategic options for continued development of ELC-100 program

Result Drivers

CARMA STUDY PROGRESS - Elicera's CARMA study showed promising results with complete metabolic response in four out of six lymphoma patients at the lowest doses, indicating potential for hard-to-treat cases

ORPHAN DRUG DESIGNATION - ELC-100 received Orphan Drug Designation in the U.S. for treating pancreatic neuroendocrine tumors, enhancing its development prospects

STRATEGIC COLLABORATIONS - Elicera entered a Material Transfer Agreement with University Hospital Tübingen to test oncolytic virus candidates, expanding research collaborations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
-SEK 0.14
Q4 Dividend
SEK 0


Analyst Coverage

Wall Street's median 12-month price target for Elicera Therapeutics AB is SEK8.50, about 73.1% above its February 12 closing price of SEK4.91

The stock recently traded at 112 times the next 12-month earnings vs. a P/E of 376 three months ago

Press Release: ID:nWkr8ZlW5V

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)